Two Distinct Gamma-2 Herpesviruses in African Green Monkeys: a Second Gamma-2 Herpesvirus Lineage among Old World Primates?

JULIE GREENSILL,¹ JULIE A. SHELDON,¹ NEIL M. RENWICK,² BRIGITTE E. BEER,^{3,4} STEVE NORLEY,⁴ JAAP GOUDSMIT,² and THOMAS F. SCHULZ^{1*}

Molecular Virology Group, Department of Medical Microbiology and Genitourinary Medicine, University of Liverpool,

Liverpool, United Kingdom¹; Department of Human Retrovirology, Academic Medical Center, University of

Amsterdam, Amsterdam, The Netherlands²; Laboratory of Molecular Microbiology, National

Institute of Allergy and Infectious Diseases, National Institutes of Health,

Bethesda, Maryland³; and Paul-Ehrlich-Institut, Langen, Germany⁴

Received 19 July 1999/Accepted 8 November 1999

Primate gamma-2 herpesviruses (rhadinoviruses) have so far been found in humans (Kaposi's sarcomaassociated herpesvirus [KSHV], also called human herpesvirus 8), macaques (*Macaca* spp.) (rhesus rhadinovirus [RRV] and retroperitoneal fibromatosis herpesvirus [RFHV]), squirrel monkeys (*Saimiri sciureus*) (herpesvirus saimiri), and spider monkeys (*Ateles* spp.) (herpesvirus ateles). Using serological screening and degenerate consensus primer PCR for the viral DNA polymerase gene, we have detected sequences from two distinct gamma-2 herpesviruses, termed *Chlorocebus* rhadinovirus 1 (ChRV1) and ChRV2, in African green monkeys. ChRV1 is more closely related to KSHV and RFHV, whereas ChRV2 is closest to RRV. Our findings suggest the existence of two distinct rhadinovirus lineages, represented by the KSHV/RFHV/ChRV1 group and the RRV/ChRV2 group, respectively, in at least two Old World monkey species. Antibodies to members of the RRV/ChRV2 lineage may cross-react in an immunofluorescence assay for early and late KSHV antigens.

Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8 (HHV8) (9), is found in all clinical forms of Kaposi's sarcoma, in primary effusion lymphomas (7, 8, 9), and in some cases of multicentric Castleman's disease (14, 27). KSHV is currently classified as a member of the rhadinovirus subgroup of gammaherpesviruses (9, 23). Rhadinoviruses have been found in many species, including cattle, mice, and both Old World and New World primates (1, 2, 3, 9, 11, 12, 17, 21, 22, 25). Viruses that infect New World monkeys include herpesvirus saimiri (HVS), which infects the squirrel monkey, and herpesvirus ateles (HVA), which infects the spider monkey (1, 2, 3). Other than humans, the macaques of Asia are the only Old World primate species documented thus far to harbor rhadinoviruses. Rhesus rhadinovirus (RRV) is widespread among rhesus macaques (Macaca mulatta), grows well in tissue culture (11), and has been fully sequenced (25). Its genome organization is very similar to that of KSHV, with homologues of several potentially pathogenic KSHV genes, including those for K1, vIL-6, vIRFs, a D-type cyclin, vFLIP, G-protein-coupled receptor, and the membrane protein K15 (16, 25). However, of those KSHV genes that have been tentatively linked to pathogenicity, RRV lacks a K12 homologue and has only one vMIP, in contrast to the three in KSHV (25). Because of this extensive similarity between RRV and KSHV, RRV has been proposed as the macaque equivalent of KSHV, and macaques infected with RRV are potentially a suitable animal model for KSHV infection. Recently, coinfection of rhesus monkeys with RRV and simian immunodeficiency virus (SIV_{mac239}) was implicated in the induction of multicentric lymphoproliferative disorder, reminiscent of multicentric Castleman's disease (31).

However, degenerate consensus primer PCR for the herpesvirus DNA polymerase and glycoprotein B genes has identified other rhadinovirus sequences in macaques suffering from retroperitoneal fibromatosis (RF) (21). RF is a mesenchymal neoplasm with vascular components and is also associated with simian retrovirus 2, which causes immunosuppression and an AIDS-like disease in macaques (6, 21, 28). Because of these features, RF in macaques had previously been suggested as an animal model for KS (28). Both the rhesus macaque and the pigtailed macaque (Macaca nemestrina) harbor RF herpesviruses (RFHVMm and RFHVMn) which appear to be more closely related to KSHV than KSHV is to RRV (5, 21). In view of reports that some currently circulating KSHV strains may have undergone a recombination event with a related rhadinovirus (15, 18, 19, 32), and the high prevalence of KSHV in sub-Saharan Africa (reviewed in reference 24), we decided to investigate the existence of KSHV-related viruses in African primates.

To determine the seroprevalence of KSHV-related viruses, we studied sera from 78 captive African green monkeys (AGMs), housed at the Paul-Ehrlich-Institut, Langen, Germany, including three subspecies of Chlorocebus aethiops: C. aethiops aethiops (grivet), C. aethiops pygerythrus (vervet), and C. aethiops sabaeus (sabaeus). Some animals were naturally infected with SIV_{AGM} and simian T-lymphotrophic virus type 1. None of the animals had been housed with species other than AGMs at the institute. The sera were tested for crossreactivity with KSHV orf65/VP19 by enzyme-linked immunosorbent assay (26) and for unspecified early and late antigens by immunofluorescent antibody assay (IFA) (Advanced Biotechnology Inc., Columbia, Md.) (10). Sera from six animals (7.8%) reacted against orf65/VP19 alone, and sera from 37 (47.4%) reacted in the lytic IFA. Sera from only two (2.5%) animals reacted in both assays. Fifty sera were also tested for

^{*} Corresponding author. Mailing address: Department of Medical Microbiology and G.U. Medicine, University of Liverpool, Duncan Building, Daulby St., Liverpool L69 3GA, United Kingdom. Phone: 44-151-7064381. Fax: 44-151-7065805. E-mail: tschulz@liv.ac.uk.

Desition in VSUN



FIG. 1. Positions of primers for consensus and virus-specific (ChRV1 and ChRV2) PCR for DNA polymerase.

antibodies to the latency-associated nuclear antigen (LANA) by IFA (13, 26), but none were positive.

In a separate study carried out in the Department of Human Retrovirology at the University of Amsterdam (N. Renwick et al., unpublished data), 201 plasma or serum samples from *Cercopithecus, Chlorocebus, Miopithecus, Cercocebus, Macaca, Mandrillus, Colobus, Presbytis, Pan, Pongo, Callithrix, Cebus, Lagothrix, Saguinus* and *Saimiri* species were screened for antibodies to orf73 (LANA) or orf65/VP19 as previously described (20). Three were found to have antibodies to recombinant orf65/VP19, seven had antibodies against recombinant orf73 (LANA), and three had antibodies in both assays. Positive animals included *Chlorocebus aethiops, Chlorocebus aethiops pygerythrus, Cercopithecus albogularis, Cercopithecus ascanius* (two), *Cercopithecus cephus, Cercopithecus mona*, Cercopithecus nictitans, Cercopithecus pogonias, Colobus guereza, Macaca nemestrina, Macaca sylvanus, and Papio cynocephalus anubis.

We initially chose five animals (one vervet, three grivets, and one unknown subspecies) from the Paul-Ehrlich-Institut AGMs with cross-reactive antibodies against orf65/VP19 and attempted to amplify herpesvirus DNA polymerase sequences from peripheral blood mononuclear cell (PBMC) DNA (extracted with the Qiagen whole-blood kit) by consensus PCR based on the method previously described (21). We modified the reported primers after including sequence from RFHVMm, RFHVMn, and RRV (11, 21, 25) and designed an additional primer (SVCA) to allow amplification of a longer DNA polymerase sequence fragment (Fig. 1; Table 1). PCR cycling conditions were 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min,

Primer	Orientation	$5' \rightarrow 3'$ sequence ^a	genome ^b	
			Start	End
Degenerate				
GDTD1B ^c	_	CGGCATGCGACAAACACGGAGTCNGTRTCNCCRTA	13643	13610
$\Delta QAHNA^{d}$	+	CCCAGTATCATNCARGCRCACAA	13133	13154
$\Delta VYGA^d$	+	ACMTGTAACGCGGTKTACGGSTTYACVGG	13409	13437
$\Delta PCLNA^{d}$	+	GTCGCCTCTGGCATCCTVCCDTGCMTNAA	13439	13467
ΔKMLEA^d	+	CAGGGCAGGAARATGCTGGARACRTCNMAGGC	13490	13521
SVCA	+	CCAGYGTNTGYGTKAACG	11784	11801
ChRV1 specific				
Z8F1	+	ACGATGTTATTTCTACACCCGCG	11812	11834
Z8F2	+	GAATCTAACGTCGACGCGACCAG	12050	12072
Z8R1	_	CTCATGGACCTCAAACACGGATC	12607	12584
Z8R2	_	GCTGGAGGTCTTCCCATCCGC	12200	12180
Z8rev1	—	TGAAGTGGGCTTCTGTCC	13602	13584
Z8rev2	—	TCTGTCTTTGCAATAGGTGGC	13573	13562
Z8rev3	_	AGTGTGGAGTAACAGAGG	13171	13155
ChRV2 specific				
L1F1	+	CCGGACGGGACCTGCACCTG	13178	13197
L1F2	+	TACGAAACGTTCGCGCTCAGCG	13221	13242
L1R1	_	ACGCGGAATCTCGCGCCGGG	13605	13585
L1R2	_	GCAGCTCGTCCGGGGTCAGG	13552	13533
L1rev1	_	ACGACGCGGAATCTCGCGCCGGG	13602	13585

TABLE 1. Sequences of primers used for consensus and virus (ChRV1 and ChRV2)-specific PCR for DNA polymerase

^a N indicates A, G, C, or T; R indicates A or G; M indicates A or C; K indicates G or T; S indicates G or C; Y indicates C or T; V indicates C, G, or A.

^b Nucleotide numbers as in reference 23. Positions for virus-specific primers correspond to equivalent residues in the KSHV genome.

^c Described in reference 21.

^d Modified from primers described in reference 21.

TABLE 2. Nucleotide and amino acid identities between ChRV1, ChRV2, and other gammaherpesviruses

	% Identity with ^a					
Virus	Chl	RV1	ChR	2		
	Nucleotide	Protein	Nucleotide	Protein		
KSHV	70.9 (66.6)	79.5 (78.3)	65.9	76.2		
ChRV1			60.6	70.9		
ChRV2	65.4 (ND)	70.9 (ND)				
RFHVMm	68.5 (ND)	81.5 (ND)	60.8	70.2		
RFHVMn	72.2 (ND)	82.8 (ND)	63.0	72.2		
RRV	63.5 (59.9)	68.2 (67.7)	84.1	88.7		
HVS	60.6 (50.6)	64.2 (61.9)	55.7	70.9		
HVA	61.3 (49.5)	64.9 (61.6)	52.9	68.2		
EBV	59.1 (50.1)	57.6 (67.6)	60.1	57.6		

^a Numbers refer to values obtained in a comparison of the 454-bp fragment, which is available for all viruses. Numbers in parentheses indicate identity for the 1,802-bp fragment, which is not available for ChRV2, RFHVMm, and RF-HVMn. ND, sequence not determined.

for 30 cycles. After three rounds of heminested PCR (GDTD1B and Δ VYGA in the initial round, followed by GDTD1B and Δ PCLNA, followed by GDTD1B and Δ KMLEA [Fig. 1; Table 1]), a fragment of 88 bp (excluding primer sequence) with 48.9% nucleotide identity with KSHV was obtained from animal Z8, a vervet monkey. Specific reverse primers (Z8rev1 and Z8rev2 [Fig. 1; Table 1]) were designed from this sequence and used in nested PCRs with the primer Δ QAHNA to obtain 454 bp of viral sequence (excluding primers). Another heminested PCR, using Z8rev2, a new specific primer Z8rev3, and SVCA (Fig. 1; Table 1) then yielded a further 1,348 bp of viral sequence. After all sequences were assembled, 1,802 bp (excluding primers) were obtained for this virus, termed Chlorocebus rhadinovirus 1 (ChRV1). A similar screen by consensus PCR of another 21 PBMC DNA samples from animals with cross-reactive antibodies in the IFA and 7 with no evidence of cross-reactivity yielded a markedly different herpesvirus DNA polymerase sequence from a seronegative monkey, L1. The virus was termed ChRV2. By using a PCR strategy similar to that used for ChRV1, but with ChRV2-specific primers (L1rev1 and L1R2 [Fig. 1; Table 1]), 454 bp of sequence (excluding primers) was determined for ChRV2.

A comparison of nucleotide and amino acid identities among primate rhadinoviruses (Table 2) indicates that ChRV1 is most closely related to RFHVMn, RFHVMm, and KSHV (72.2, 68.5, and 70.9% nucleotide identity, respectively). It appears to be least closely related to the two New World rhadinoviruses HVS and HVA (60.6 and 61.3% nucleotide identity), with an intermediate degree of relatedness to RRV and ChRV2 (63.5 and 65.4% identity) (Table 2). When ChRV2 is compared with all these viruses, the same three groupings are apparent, with ChRV2 being closest to RRV (84.1% nucleotide identity), most distant from HVS and HVA (55.7 and 52.9% nucleotide identity), and the KSHV/RFHV/ ChRV1 group in an intermediate position (60.6 to 65.9% nucleotide identities). The same three groupings are also seen when the GC content is tabulated and, to some extent, also for the CpG ratios of individual viruses (Table 3).

An alignment of the amino acid sequence corresponding to the 1,802-bp fragment is shown in Fig. 2 and reveals sequence motifs shared by ChRV2 and RRV or the KSHV/RFHV/ ChRV1 group. By maximum likelihood analysis of the 1,802-bp DNA sequence (which is not available for ChRV2 and RFHVMm/RFHVMn) (Fig. 3a), ChRV1 appears most closely

TABLE 3. GC content and CpG dinucleotide frequencies in DNA polymerase fragments from gammaherpesviruses

	GC con	tent (%)	CpG ratio ^a			
Virus	1,802-bp equivalent	454-bp equivalent	1,802-bp equivalent	454-bp equivalent		
KSHV	53.9	54.3	0.80	0.91		
ChRV1	54.1	54.5	0.96	0.93		
ChRV2	ND^b	63.8	ND	1.15		
RFHVMm	ND	51.0	ND	1.13		
RFHVMn	ND	55.9	ND	0.96		
RRV	59.0	59.8	1.18	1.25		
HVA	36.2	38.9	0.45	0.29		
HVS	35.2	40.0	0.29	0.28		
EBV	62.6	64.9	0.70	0.73		

^a Observed frequency/expected frequency of CpG dinucleotides for the mononucleotide composition. (Expected frequency = proportion C \times proportion G \times [sequence length -1].) b ND, sequence not determined.

related to KSHV, followed by RRV and, in a separate branch, by the New World rhadinoviruses HVS and HVA. The same branching order was obtained with other phylogenetic methods, including neighbor joining analysis and parsimony (not shown), and supported by high bootstrap values (Fig. 3a). Similar analyses were carried out on the 454-bp DNA polymerase fragment available for other rhadinoviruses, including ChRV2 and RFHVMm/RFHVMn. A neighbor joining tree of the corresponding 151-amino-acid protein sequence (Fig. 3b) illustrates the existence of three separate lineages among rhadinoviruses, one for the New World viruses HVS and HVA and two for the Old World viruses. In spite of being derived from different species living, respectively, in Asia and Africa, RRV and ChRV2 cluster together, as do KSHV, ChRV1, and RFHVMm/RFHVMn. Furthermore, viruses from the same species (ChRV1 and ChRV2 from AGMs and RRV and RFHVMm from rhesus macaques) group separately from each other. This strongly suggests that at least two Old World primate species harbor two fairly distinct rhadinovirus lineages. In humans, one of these lineages is represented by KSHV, whereas the other lineage currently lacks a known representative

Further specific primers were designed (Z8F1, Z8F2, Z8R1, and Z8R2 for ChRV1 and L1F1, L1F2, and L1R1 [with L1R2] for ChRV2 [Fig. 1; Table 1]) and used to screen DNA from PBMCs of 68 AGMs for the presence of either virus. PCRs were repeated to ensure the veracity of results, in some cases on new aliquots of PBMCs. Six other monkeys were found to be infected with an ChRV1-like virus; an animal from the Amsterdam panel (a red-tailed monkey, Cercopithecus ascanius) and five AGMs from the Paul-Ehrlich-Institut (two grivets and three unknown subspecies). Hence, ChRV1-like viruses appear to be infrequent among captive African monkeys, or they are difficult to detect because of low viral load. In this, they resemble the other members of this lineage, KSHV and RFHVMm/RFHVMn; KSHV is detected in only approximately 10 to 20% of serologically reactive individuals (4, 24, 30), although concurrent human immunodeficiency virus type 1 infection, or iatrogenic immunosuppression, markedly increases the risk of developing Kaposi's sarcoma in KSHVinfected individuals (4, 26, 30), and RFHVMm-RFHVMn is detected only in animals with RF or after immune suppression (6). Sequence analysis of the PCR products obtained from these animals with the ChRV1 diagnostic primers (Z8F2 and Z8R2; 107 bp of sequence, excluding primers) indicated that

	SVCA	Z8F1							
									80
KSHV		FRQRCYFYTL	APQGVNLTHV	LQQALQAGF*	*GRASCGFST	EPVRKKILRA	YDTQQYAVQK	ITLSSSPMMR	TLSDRLTT*C
DEUVIO		R	br	VAI*	~TP-A-T-	-T-KA	KI-D-I-	VVA	AA^-
REHVMIN		•••••	• • • • • • • • • • • •	•••••	•••••	• • • • • • • • • • • •		• • • • • • • • • • • •	•••••
ChRV2		••••			••••		•••••		
RRV		OVAK	V-A-I-VI	KNTA*	*A	RR-N-RKT	VAEHP-TE	GS-LS	VA*-
HVA		-G-KIVK	V-E-G-I-YL	MKNEKL*	*-*PR-SYQ-	-L-KSR	PDEHE-F-	V-IHSVY	KVY-VA*N
HVS		-GNVK	V-E-G-I-YL	IKNEK-*	*S*PAYQ-	-A-KSR	PEEHD-F-	V-VLSVY	KIS-VS*N
EBV		-G-QAAS	LDVEFA	VLSK-STF	DR-TP-RV-V	-K-TRRSIMG	-GNHAGDYHK	HPNSVC	HVATW-QDKH
	285	r2			7	882			
	81	_				UTVE.			170
KSHV	GCEVEESNVD	ATRREVIDEG	FSTEGWYECS	NPAPRTOARD	SWTELEFDCS	WEDLKEIPER	TEWPPYSTLS	FDIECMGEKG	FPNATODEDM
ChRV1		-TRE	A-T	H-ELSG	G	OLR	0BM	A-	RRV
RFHVMm					* *				
RFHVMn									
ChRV2									
RRV		-V	-TS-A	RATL	AR-A	SVQAD-	SDR-VA	TA-	CR-G-A
HVA	IT	II-NN	Т-К	SACFTN	-Y-DIG	YNE-HA	N-MA	I	C-KNEG-L
HVS	T	I-ND	T-K	SACITN	-H-DIG	YYE-HAD-	N-M-	I	C-KNEG-L
EBV	RIA	-TND	-vS-R	RAIL-H	-YAYE	VGSVRR-D	SSS-QA-A	E-	TNEA-L
	171								260
KSHV	TTOTSCVLHT	VGNDKPYTR*	MLLGLGTCDP	LPGVEVFEFP	SEYDMLAAFL	SMLRDYNVEF	TTGYNTANED	LPYTTARATO	VYDEKLODET
ChRV1	-LF	A-DKSO*	ISE-	-E-T-IL	F	AD	L	T	NID-KN
RFHVMm							-		
RFHVMn									
ChRV2									
RRV	VF-T	TREGA-NPPN	I-FSV	I-DTD-L	VEDSY	A-IFE-D-	LS	L-TS-	NLR-NEY-
HVA	FWQ	TPDT*-KN	SAA	VEDSY	AHG-F	TII	S	L-D	I-NIS-YS
HVS	FWH	A-ALDT*N	SASA	VENTY	IHG-F	-LIFI	S	L-D	I-NIS-YS
EBV	-LWS	T-EEAGRY-R	ITED	IEY	LYF	QLILSI	vv	WLDRH	I-SINPASLG
	ZSF	R1							
	261								350
KSHV	KIKTGSVFEV	HQPRGGSDGG	NFMRSQSKVK	ISGIVPIDMY	QVCREKLSLS	DYKLDTVAKQ	CLGRQKDDIS	YKDIPPLFKS	GPDGRAKVGN
DEUM		-E-T	G-T	A	D		K	-KK-	-AA1-K
PFUVMp	• • • • • • • • • • • •		• • • • • • • • • • • •	•••••	••••		• • • • • • • • • • •	•••••	•••••
ChRV2					•••••		• • • • • • • • • • •	•••••	
RRV			C		•••••		• • • • • • • • • • •		
				-A		R-	GK-E-V-	R-	
HVA	RV-SI-O-	-M-KDM**-N	GVI-	-A	TKD	R- NDH	GK-E-V-	~R-	ET-R
HVA HVS	RV-SI-Q- RVI-O-	-M-KDM**-N -T-KDT**-N	GVI- GVI-	-AIA	IKD IKD	R- NDH NNH	GK-E-V- -I-AK-E-V- -I-AK-E-V-	~R- ~M-	EI-R EI-L
HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C	-M-KDM**-N -T-KDT**-N RR-HDA**-K	GVI- GVI- G-L-ANTR	-A IA -T-LI	IKD IKD AD	R- NDH NNH RH	GK-E-V- -I-AK-E-V- -I-AK-E-V- LAK-E-VH	RM- MM- ERAA	EI-R ERRL-M
HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C	-M-KDM**-N -T-KDT**-N RR-HDA**-K	GVI- GVI- G-L-ANTR	-AIA IA -T-LI	IKD IKD AD	R- NDH NNH RH	GK-E-V- -I-AK-E-V- ~I-AK-E-V- LAK-E-VH	RR- MM- ERAA	EI-R EI-L ERRL-M
HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C	-M-KDM**-N -T-KDT**-N RR-HDA**-K	GVI- GVI- G-L-ANTR	-A IA -T-LI	IKD IKD AD	R- NDH NNH RH	GK-E-V- -I-AK-E-V- -I-AK-E-V- LAK-E-VH	R	EI-R EI-L ERRL-M
HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C	- <u>L</u>	GVI- GVI- G-L-ANTR	-AIA IA -T-LI	IKD IKD AD	R- NDH NNH RH	GK-E-V- -I-AK-E-V- -I-AK-E-V- LAK-E-VH	RR- MM- ERAA	EI-R EI-L ERRL-M 440
HVA HVS EBV KSHV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM	-M-KDM**-N -T-KDT**-N RR-HDA**-K	GVI- GVI- G-L-ANTR EISEIAKLAK	-AIA IA -T-LI	IKD IKD AD QQIRVFSCLL	EAAATEGYIL	GK-E-V- -I-AK-E-V- -I-AK-E-V- LAK-E-VH	YQGATVISPS	GI-R EI-L ERRL-M 440 PGFYDDPVLV
HVA HVS EBV KSHV ChRV1	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM	GVI- GVI- G-L-ANTR EISEIAKLAK	-A IA -T-LI IPTRRVLTDG	IKD IKD AD QQIRVFSCLL	R- NDH NNH RH EAAATEGYIL	GK-E-V- -I-AK-E-V- -I-AK-E-V- LAK-E-VH PVPKGDAVSG RTG-	YQGATVISPS	GI-R EI-L ERRL-M 440 PGFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMm FFHVMm	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM	GVI- GVI- G-L-ANTR EISEIAKLAK AR	-AIA IA -T-LI IPTRRVLTDG	IKD IKD AD QQIRVFSCLL		GK-E-V- -I-AK-E-V- I-AK-E-V- LAK-E-VH PVPKGDAVSG RTG-	RM- MM- ERAA YQGATVISPS I	EI-R EI-L ERRL-M 440 PGFYDDPVLV
HVA HVS EBV ChRV1 RFHVMm RFHVMm ChRV2	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM	GVI- GVI- G-L-ANTR EISEIAKLAK AR	-A IA -T-LI IPTRRVLTDG	IKD IKD AD QQIRVFSCLL	R- NDH NRH EAAATEGYIL K	GK-E-V- -I-AK-E-V- -I-AK-E-V- LAK-E-VH PVPKGDAVSG RTG-	RM- MM- ERAA YQGATVISPS I	EI-R EI-L ERRL-M 440 PGFYDDPULV
HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm RFHVMn ChRV2 RRV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM	GVI- GVI- G-L-ANTR EISEIAKLAK AR	-A		RH		RRR	EI-R EI-L ERRL-M PGFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMn ChRV2 RRV HVA	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	KDM**-N KDM**-N KDT**-N KDT**-N KDT**-N KDT*	GVI- GVI- G-L-ANTR EISEIAKLAK AR	-A	QQIRVFSCLL		GK-E-V- -I-AK-E-V- I-AK-E-V- LAK-E-VH PVPKGDAVSG RTG- 	RM- MM- ERAA YQGATVISPS I 	
HVA HVS EBV KSHV ChRV1 RFHVMn RFHVMn ChRV2 RRV HVA HVS	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM KM-MI KMF-K	GVI- GVI- G-L-ANTR EISEIAKLAK -AR	-A	QQIRVFSCLL		GK-E-V- -I-AK-E-V- I-AK-E-V- LAK-E-VH PVPKGDAVSG RTG- 	RM- MM- ERAA YQGATVISPS I N-I FT-I FN-I	
HVA HVS EBV KSHV ChRV1 RFHVMn RFHVMn ChRV2 RRV HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I ML L L	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM K	GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	QQIRVFSCLL		GK-E-V- -I-AK-E-V- LAK-E-VH PVPKGDAVSG TG- 	RM- MM- ERAA YQGATVISPS I FN-I FN-I FQ-L	
HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm ChRV2 RRV HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I		GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	QQIRVFSCLL		GK-E-V- -I-AK-E-V- I-AK-E-V- LAK-E-VH PVPKGDAVSG TG- TG- TG- TG- 	RM- MM- ERAA YQGATVISPS I I FN-I FN-I FN-I Q-L	GI-R EI-R ERRL-M PGFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm ChRV2 RRV HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM 	GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	QQIRVFSCLL		GK-E-V- -I-AK-E-V- LAK-E-VH PVPKGDAVSG RTG- TG- TPEGQG- SNNVNTD- SNDVNAD- -M-SASDRD-	RM- MM- 	
HVA HVS EBV ChRV1 RFHVMm ChRV2 RFVMn ChRV2 RRV HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM KM-MI KMF-K KKF-MI NH-VI	GVI- GVI- G-L-ANTR EISEIAKLAK -AR 	-A	QQIRVFSCLL 	R-NF AQK-NF	GK-E-V- -I-AK-E-V- I-AK-E-VH PVPKGDAVSG RTG- 	RM- MM- ERAA YQGATVISPS I N-I FT-I FN-I Q-L	GI-R EI-R ERL-M 9GFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMn RFHVMn ChRV2 RRV HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM K	GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	QQIRVFSCLL 	R-NF AQK-NF	GK-E-V- -I-AK-E-V- I-AK-E-V- LAK-E-VH PVPKGDAVSG RTG- 	RM- MM- ERAA YQGATVISPS I FN-I FN-I FN-I FQ-L	
HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm ChRV2 RFW HVA HVS EBV KSHV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM KMF-K KMF-K K	GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	□KD □KD AD QQIRVFSCLL 		GK-E-V- -I-AK-E-V- I-AK-E-V- LAK-E-VH PVPKGDAVSG RTG- TFG- 	RM- MM- ERAA YQGATVISPS I FN-I FN-I FN-I FQ-L	GS EI-R ERRL-M PGFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMm ChRV2 RRV HVS EBV KSHV ChRV1	RV-SI-Q- RVI-Q- -RA-G-C 351 YCVIDSVLVM I		GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	1KD 1KD AD QQIRVFSCLL 		GK-E-V- -I-AK-E-V- I-AK-E-VH PVPKGDAVSG RTG- TPEGQG- SNVNTD- SNVNTD- SNDVNAD- H-SASDRD- LAKLLTVWLA -SAT-S		GI-R EI-R ERL-M 440 PGFYDDPVLV NNA SNS 530 SCTDPALKTI ATMR
HVA HVS EBV KSHV ChRV1 RFHVMn ChRV2 RRV HVS EBV KSHV ChRV1 RFHVMm	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM KKM-MI KKF-MI NH-VI QAHNA Z8re	GVI- GVI- G-L-ANTR EISEIAKLAK -AR 	-A IA -T-LI IPTRRVLTDG 	QQIRVFSCLL QQIRVFSCLL 		GK-E-V- -I-AK-E-V- I-AK-E-VH PVPKGDAVSG RTG- TFEGQG- SNNVNTD- SNDVNAD- -M-SASDRD- LAKLLTVWLA -SAT-S S-ST-T	R	GT-R EI-R ERL-M 9GFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm HVS EBV KSHV ChRV1 RFHVMm RFHVMm	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM	GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	QQIRVFSCLL QQIRVFSCLL 				GTMR EI-R ERL-M 440 PGFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMm ChRV2 RFVMn ChRV2 EBV KSHV ChRV1 RFHVMm RFHVMm RFHVMm	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 		GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	□KD □KD AD QQIRVFSCLL 			RA	
HVA HVS EBV KSHV ChRV1 RFHVMm ChRV2 RRV HVS EBV KSHV ChRV1 RFHVMm RFHVMm RFHVMm RFHVMm RFHVMm	RV-SI-Q- RVI-Q- -RA-G-C 351 YCVIDSVLVM I		GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	□KD □KD AD QQIRVFSCLL 		GK-E-V- -I-AK-E-V- -I-AK-E-VH PVPKGDAVSG RTG- 	RA	
HVA HVS EBV KSHV ChRV1 RFHVMn ChRV2 RRV HVA HVS EBV KSHV ChRV1 RFHVMn RFHVMn RFHVMn RFHVMn RFHVMn	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM KKM-MI KKF-MI KKF-MI	GVI- GVI- G-L-ANTR EISEIAKLAK -AR 	-A	QQIRVFSCLL 				GI-R EI-R ERRL-M PGFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm ChRV2 RFV HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm RFHVMm ChRV2 RFV HVA	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV 	GVI GVI G-L-ANTR EISEIAKLAK AR 	-A	IKD AD AD AD AD A A IF2 TFVLSGGPVH 				
HVA HVS EBV KSHV ChRV1 RFHVMm ChRV2 RRV HVS EBV KSHV ChRV1 RFHVMn RFHVMn RFHVMn ChRV2 RRV RFV KSHV ChRV1 RFHVM	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM KMF-K KMF-K KKF-MI NH-VI 204HNA Z8rc IQAHNLCYST	GVI- GVI- G-L-ANTR 	-A	IKD IKD AD QQIRVFSCLL			YQGATVISPS 	
HVA HVS EBV KSHV ChRV1 RFHVMm ChRV2 RRV HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm RFHVMm RFHVMm ChRV2 RRV HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 		GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	IKD IKD AD QQIRVFSCLL		GR-E-V- -IAK-E-V- IAK-E-VH PVPKGDAVSG TG- 	RM- MM-	
HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm ChRV2 EBV KSHV ChRV1 KSHV ChRV1 RFHVMm RFHVMm RFHVMm RFHVMm RFHVMm RFHVMM	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM KMF-K KKF-MI	GVI GVI G-L-ANTR EISEIAKLAK -AR 	-A	QQIRVFSCLL 		GR-E-V- -I-AK-E-V- I-AK-E-V- LAK-E-VH PVPKGDAVSG TG- 		GI-R EI-R ERL-M ERL-M ERL-M
HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm ChRV2 REV KSHV ChRV1 RFHVMm RFHVMm ChRV2 RFV HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 		GVI GVI G-L-ANTR EISEIAKLAK AR 	-A	IKD AD AD AD AD AD A IF2 TFVLSGGPVH 		GK-E-V- -I-AK-E-V- I-AK-E-V- LAK-E-VH PVPKGDAVSG TG- TG- TG- 	RRR	
HVA HVS EBV KSHV ChRV1 RFHVMm ChRV2 RRV HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm ChRV2 RRV HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 		GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A IA -T-LI IPTRRVLTDG 	IKD IKD AD QQIRVFSCLL			YQGATVISPS N	
HVA HVS EBV KSHV ChRV1 RFHVMn ChRV2 RRV HVA HVS EBV KSHV ChRV1 RFHVMn RFHVMn RFHVMn ChRV2 RRV HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM KM-MI KMF-K KKF-MINH-VI 2AHNA Z8rc IQAHNLCYST IQAHNLCYST 	GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A IA -T-LI -T-LI 	IKD IKD AD QQIRVFSCLL		GR-E-V- -IAK-E-V- IAK-E-V- LAK-E-VH PVPKGDAVSG TG- 		440 PGFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm ChRV2 RFV ChRV1 KSHV ChRV1	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM	GVI GVI G-L-ANTR EISEIAKLAK -AR 	-A	QQIRVFSCLL 				440 PGFYDDPVLV PGFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMm ChRV2 RFHVMn ChRV1 RFHVMn ChRV2 RRV HVS EBV KSHV HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I M QA 441 VDFASLYPSI 531 LDKQQLAIKV	-M-KDM**-N -T-KDT**-N RR-HDA**-K DLLLRFQTHV RM-MI KMF-K KKF-MI NH-VI 204NNA Z8rc IQAHNA Z8rc IQAHNA Z8rc 	GVI- GVI- G-L-ANTR EISEIAKLAK AR 	-A	IKD IKD AD QQIRVFSCLL				
HVA HVS EBV KSHV ChRV1 RFHVMm ChRV2 RRV HVA HVS EBV KSHV ChRV1 RFHVMm RFHVMm ChRV2 RRV HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 		GVI GVI G-L-ANTR EISEIAKLAK AR 	-A	IKD IKD AD QQIRVFSCLL			YQGATVISPS	440 PGFYDDPVLV
HVA HVS EBV KSHV ChRV1 RFHVMn ChRV2 RRV HVA HVS EBV KSHV ChRV1 RFHVMn RFHVMn ChRV2 RRV HVA HVS EBV	RV-SI-Q- RVI-Q- RA-G-C 351 YCVIDSVLVM I 	KDM**-N _T-KDM**-N RR-HDA**-K DLLLRFQTHV RM KKF_KI KKF_KI KKF_KI KKF_KI IQAHNLCYST AVYGA TCNAVYGFTG 	GVI GVI G-L-ANTR EISEIAKLAK AR 	-A	IKD IKD AD QQIRVFSCLL				G

and virus-specific primers are shown. The origin of sequences is as described in the legend to Fig. 3a.



FIG. 3. (a) DNA maximum likelihood tree for the 1,802-bp fragment (primers SCVA and GDTD1B) of DNA polymerase. Sequences were aligned by using CLUSTALX and analyzed by using the DNAML program (PHYLIP version 3.5c; J. Felsenstein and the University of Washington). One hundred replica samplings were subjected to bootstrap analysis (SEQBOOT). The tree is unrooted. Other sequences included and their EMBL accession numbers are as follows: HHV1/HSV1 (X04771), HHV2/HSV2 (M16321), HHV3/VZV (X04370), HHV4/Epstein-Barr virus (V01555), HHV5/HCMV (AF133589), HHV6A (X83413), HHV7 (U43400), HHV8/KSHV (U75698), HVS (X64346), HVA (HVA3) (AF083424), RFHVMm (AF005479), RFHVMn (AF005478), RRV (AF029302). (b) Neighbor-joining protein distance tree for the 151 amino acid residues encoded by the 454-bp fragment (primers ΔQAHNA and GDTD1B) of DNA polymerase. Sequences were aligned by using CLUSTALX and analyzed by using the PROTDIST and NEIGHBOR programs in PHYLIP. One hundred replica samplings were analyzed. The tree is unrooted.

the sequences obtained from the six Chlorocebus aethiops animals, Z8 and five other positive animals, were identical. PCRs were repeated for these animals, with the same sequence being determined. The sequence from the more distantly related red-tailed monkey (Cercopithecus ascanius) (29) differed from ChRV1 by 2 nucleotides (98.1% nucleotide identity), with the substitutions A-G (KSHV nucleotide 12093 [23]), and G-A (KSHV nucleotide 12147), leading to Glu-Gly and Gly-Asp substitutions, respectively. While more extensive sequence comparisons among different cercopithecine species are required, this could indicate a higher degree of sequence conservation among ChRV1-like viruses than among RFHVs in different macaque species (21). However, we cannot currently exclude transmission of ChRV1 among cercopithecine monkeys in captivity. As determined with the ChRV2 diagnostic primers (L1F1, L1F2, L1R1, and L1R2 [Fig. 1; Table 1]), 22 AGMs (33.3%) were PCR positive for the ChRV2-type virus. This is again reminiscent of RRV, the other member of the second lineage (Fig. 3), which is easily isolated from different macaques (11, 25); serological studies, using purified RRV as the antigen, found evidence for a high prevalence of the virus (\sim 50% positivity rate) (11). We have also recently detected ChRV2-like sequences in 3 of 11 wild-caught Cercopithecus mona animals, which are quite closely related to C. aethiops and Cercopithecus ascanius species (29; Greensill et al., unpublished data).

We investigated whether detection, by PCR, of ChRV1 or ChRV2 correlated with the presence of cross-reacting antibodies to KSHV, as determined by orf65/vp19 ELISA or lytic IFA. Among 66 AGMs (18 grivets, 4 vervets, 2 sabaeus, and 42 unknown) also tested by PCR, reactivity in lytic IFA was widespread (37 of 66; 56%) but particularly high in those in which ChRV2 could be detected by PCR (16 of 22; 73.7%), compared to those in which it was not (21 of 44; 47.8%; P = 0.054). No such correlation was found between reactivity in orf65/vp19 ELISA and ChRV2 detection (0 of 22 ChRV2 PCR-positive animals had antibodies to orf65/VP19, whereas 5 of the remaining ChRV2 PCR-negative animals had orf65/VP19 antibodies). ChRV1 was detected in only seven animals in our study, so any correlation between antibody reactivity and infection with the virus is difficult to resolve. However, of the seven ChRV1 PCR positive animals, two had antibodies to orf65/VP19, three had antibodies detected in the lytic IFA, and two were nonseroreactive. Of the remaining 73 ChRV1 PCR-negative animals, 10 had antibodies to orf65/VP19.

The existence of two rhadinovirus lineages in at least two Old World monkey species could suggest the existence of a similar situation in the great apes, and perhaps in humans. The correlation of PCR-detectable ChRV2 with reactivity in lytic IFA is in accord with the concept that this assay, in particular when carried out at low serum dilutions, may detect antibodies against a related virus. Whether this explains some cases of lytic IFA reactivity in humans where KSHV infection could not be confirmed by other, more specific assays remains to be seen. Evidence for recombination of the right-hand end of the KSHV genome with a related rhadinovirus has recently been reported (15, 18, 19, 32). It is conceivable that this could have occurred as the result of a coinfection in humans with two related viruses. In this study we have found two examples, with an AGM from Paul-Ehrlich-Institut colony and the Amsterdam red-tailed monkey, of coinfection with representatives of the ChRV1 and ChRV2 groups.

If the existence of two separate lineages of gamma-2 herpesviruses in different primate species is confirmed by more extensive sequence analysis it may be necessary to derive a nomenclature that distinguishes between these two branches.

Nucleotide sequence accession numbers. The 1,802-bp sequence of ChRV1 and the 454-bp sequence of ChRV2 have been deposited in GenBank under accession no. AJ251573 and AJ251574, respectively.

We are grateful to Helen Williams for technical assistance and to D. Ablashi of Advanced Biotechnologies Inc. for providing the lytic IFA kits.

This study was supported by the Oxenhale Trust and the Northwest Cancer Research Fund.

REFERENCES

- Albrecht, J.-C. 2000. Primary structure of the *Herpesvirus ateles* genome. J. Virol. 74:1033–1037.
- Albrecht, J.-C., J. Nicholas, D. Biller, K. R. Cameron, B. Biesinger, C. Newman, S. Wittmann, M. A. Craxton, H. Coleman, B. Fleckenstein, and R. W. Honess. 1992. Primary structure of the herpesvirus saimiri genome. J. Virol. 66:5047-5058.
- Albrecht, J.-C., U. Friedrich, C. Kardinal, J. Koehn, B. Fleckenstein, S. M. Feller, and B. Biesinger. 1999. Herpesvirus ateles gene product Tio interacts with nonreceptor protein tyrosine kinases. J. Virol. 73:4631–4639.
- Ariyoshi, K., M. Schim van der Loeff, T. Corrah, F. Cham, P. M. Cook, D. Whitby, R. A. Weiss, and T. F. Schulz. 1998. Kaposi's sarcoma and human herpesvirus 8 (HHV8) in HIV-1 and HIV-2 infection in The Gambia. J. Hum. Virol. 1:193–199.
- Bosch, M. L., K. B. Strand, and T. L. Rose. 1998. Gammaherpesvirus sequence comparisons. J. Virol. 72:8458–8459.
- Bosch, M. L., E. Harper, A. Schmidt, K. B. Strand, S. Thormahlen, M. E. Thouless, and Y. Wang. 1999. Activation in vivo of retroperitoneal fibromatosis-associated herpesvirus, a simian homologue of human herpesvirus-8. J. Gen. Virol. 80:467–475.
- Cesarman, E., Y. Chang, P. S. Moore, J. W. Said, and D. M. Knowles. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences are present in AIDS-related body cavity based lymphomas. N. Engl. J. Med. 332:1186– 1191.
- Cesarman, E., P. S. Moore, P. H. Rao, G. Inghirami, D. M. Knowles, and Y. Chang. 1995. In vitro establishment and characterization of two AIDSrelated lymphoma cell-lines (BC-1 and BC-2) containing Kaposi's sarcomaassociated herpesvirus-like (KSHV) DNA sequences. Blood 86:2708–2714.
- Chang, Y., E. Česarman, M. S. Pessin, F. Lee, J. Culpepper, D. M. Knowles, and P. S. Moore. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 265:1865–1869.
- 10. Chatlynne, L. G., W. Lapps, M. Handy, Y. Q. Huang, R. Masood, A. S. Hamilton, J. W. Said, H. P. Koeffler, M. H. Kaplan, A. Friedman-Kien, P. S. Gill, J. E. Whitman, and D. V. Ablashi. 1998. Detection and titration of human herpesvirus-8-specific antibodies in sera from blood donors, acquired immunodeficiency syndrome patients, and Kaposi's sarcoma patients using a whole virus enzyme-linked immunosorbent assay. Blood 92:53–58.
- Desrosiers, R. C., V. G. Sasseville, S. C. Czajak, X. Zhang, K. G. Mansfield, A. Kaur, R. P. Johnson, A. A. Lackner, and J. U. Jung. 1997. A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus. J. Virol. 71:9764–9769.
- Efstathiou, S., Y. M. Ho, S. Hall, C. J. Styles, S. D. Scott, and U. A. Gompels. 1990. Murine herpesvirus 68 is genetically related to the gammaherpesviruses Epstein-Barr virus and herpesvirus saimiri. J. Gen. Virol. 71:1365– 1372.
- Gao, S.-J., L. Kingsley, M. Li, W. Zheng, C. Parravicini, J. Ziegler, R. Newton, C. R. Rinaldo, A. Saah, J. Phair, R. Detels, Y. Chang, and P. S. Moore. 1996. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat. Med. 2:925–928.
- 14. Gessain, A., A. Sudaka, J. Briere, N. Fouchard, M.-A. Nicola, B. Rio, M. Arborio, X. Troussard, J. Audouin, J. Diebold, and G. de The. 1996. Kaposi's sarcoma associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood 87:414–416.
- Glenn, M., L. Rainbow, F. Aurade, A. Davison, and T. F. Schulz. 1999. Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2a

of Epstein-Barr virus. J. Virol. 73:6953-6963.

- Kaleeba, J. A. R., E. P. Bergquam, and S. W. Wong. 1999. A rhesus macaque rhadinovirus related to Kaposi's sarcoma-associated herpesvirus 8 encodes a functional homologue of interleukin-6. J. Virol. 73:6177–6181.
- Moore, P. S., S.-J. Gao, G. Dominguez, E. Cesarman, O. Lungu, D. M. Knowles, R. Garber, D. J. McGeoch, P. Pellett, and Y. Chang. 1996. Primary characterization of a herpesvirus-like agent associated with Kaposi's sarcoma. J. Virol. 70:549–558.
- Nicholas, J., J. C. Zong, D. J. Alcendor, D. M. Ciufo, L. J. Poole, R. T. Sarisky, C. J. Chiou, X. Zhang, X. Wan, H. G. Guo, M. S. Reitz, and G. S. Hayward. 1998. Novel organizational features, captured cellular genes, and strain variability within the genome of KSHV/HHV8. J. Natl. Cancer Inst. Monogr. 23:79–88.
- 19. Poole, L. J., J.-C. Zong, D. M. Ciufo, D. J. Alcendor, J. S. Cannon, R. Ambinder, J. M. Orenstein, M. S. Reitz, and G. S. Hayward. 1999. Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right-hand end. J. Virol. 73:6646–6660.
- Renwick, N., T. Halaby, G. J. Weverling, N. H. Dukers, G. R. Simpson, R. A. Coutinho, J. M. Lange, T. F. Schulz, and J. Goudsmit. 1998. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS 12:2481–2488.
- Rose, T. M., K. B. Strand, E. R. Schultz, G. Schaefer, G. W. Rankin, Jr., M. E. Thouless, C.-C. Tsai, and M. L. Bosch. 1997. Identification of two homologs of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in retroperitoneal fibromatosis of different macaque species. J. Virol. 71:4138–4144.
- Rovnak, J., S. L. Quackenbush, R. A. Reyes, J. D. Baines, C. R. Parrish, and J. W. Casey. 1998. Detection of a novel bovine lymphotropic herpesvirus. J. Virol. 72:4237–4242.
- Russo, J. J., R. A. Bohenzky, M.-C. Chien, J. Chen, M. Yan, D. Maddalena, J. P. Parry, D. Peruzzi, I. S. Edelman, Y. Chang, and P. S. Moore. 1996. Nucleotide sequence of the Kaposi's sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. USA 93:14862–14867.
- Schulz, T. F. 1999. Epidemiology of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. Adv. Cancer Res. 76:121–160.
- Searles, R. P., E. P. Bergquam, M. K. Axthelm, and S. W. Wong. 1999. Sequence and genomic analysis of a rhesus monkey rhadinovirus with similarity to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. J. Virol. 73:3040–3053.
- 26. Simpson, G. R., T. F. Schulz, D. Whitby, P. M. Cook, C. Boshoff, L. Rainbow, M. R. Howard, S.-J. Gao, R. A. Bohenzky, P. Simmonds, C. Lee, A. de Ruiter, A. Hatzakis, R. S. Tedder, I. V. D. Weller, R. A. Weiss, and P. S. Moore. 1996. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 349:1133–1138.
- Soulier, J., L. Grollet, E. Oskenhendler, P. Cacoub, D. Cazals-Hatem, P. Babinet, M.-F. d'Agay, J.-P. Clauvel, M. Raphael, L. Degos, and F. Sigaux. 1995. Kaposi's sarcoma associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276–1280.
- Tsai, C. C., C.-C. Tsai, S. T. Roodman, and M.-D. Woon. 1990. Mesochymoproliferative disorders (MPD) in simian AIDS associated with SRV-2 infection. J. Med. Primatol. 19:189–202.
- van der Kuyl, A. C., C. L. Kuikun, J. T. Dekker, and J. Goudsmit. 1995. Phylogeny of African monkeys based upon mitochondrial 12S rRNA sequences. J. Mol. Evol. 40:173–180.
- 30. Whitby, D., M. R. Howard, M. Tenant-Flowers, N. S. Brink, A. Copas, C. Boshoff, T. Hatziouannou, F. E. A. Suggett, D. M. Aldam, A. S. Denton, R. F. Miller, I. V. D. Weller, R. A. Weiss, R. S. Tedder, and T. F. Schulz. 1995. Detection of Kaposi's sarcoma-associated herpesvirus (KSHV) in peripheral blood of HIV-infected individuals predicts progression to Kaposi's sarcoma. Lancet 364:799–802.
- 31. Wong, S. W., E. P. Bergquam, R. M. Swanson, F. W. Lee, S. M. Shiigi, N. A. Avery, J. W. Fanton, and M. K. Axthelm. 1999. Induction of B cell hyperplasia in simian immunodeficiency virus-infected rhesus macaques with the simian homologue of Kaposi's sarcoma-associated herpesvirus. J. Exp. Med. 190:827–840.
- 32. Zong, J. C., D. M. Ciufo, D. J. Alcendor, X. Wan, J. Nicholas, P. J. Browning, P. L. Rady, S. K. Tyring, J. M. Orenstein, C. S. Rabkin, I. J. Su, K. F. Powell, M. Croxson, K. E. Foreman, B. J. Nickoloff, S. Alkan, and G. S. Hayward. 1999. High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations. J. Virol. 73:4156–4170.